SCYNEXIS Appoints David Angulo, M.D., as Chief Medical Officer
RESEARCH TRIANGLE PARK, N.C., May 14, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the appointment of David Angulo, M.D., as Chief Medical Officer, effective June 1, 2015. Dr. Angulo will be responsible for advancing the company's clinical development strategy and clinical operations for SCY-078, SCYNEXIS' lead clinical asset, currently in Phase 2 clinical development for the treatment of invasive fungal infections.
"David brings a wealth of relevant experience to SCYNEXIS, both through his tenure as an infectious disease physician and through clinical and corporate roles where he was instrumental in securing FDA approval for ten different products in infectious disease and dermatology," said Marco Taglietti, M.D., SCYNEXIS' Chief Executive Officer. "His proven track record in developing antifungals and his broad expertise in drug development will strengthen our clinical development efforts and support the continued development of SCY-078, a novel oral and intravenous antifungal compound."
Prior to joining SCYNEXIS, Dr. Angulo was Vice President, Research and Development with Brickell Biotech. Prior to that, he held various senior positions at Stiefel, a GSK company, including head of the clinical and medical departments. Dr. Angulo was also responsible for several development programs in the anti-infective area at Schering-Plough Corporation, and before that, he was an infectious disease physician in a pediatric hospital. Dr. Angulo has an M.D. from the Universidad de Guadalajara, Mexico, and has post-graduate degrees in pediatrics and infectious diseases.
"Physicians are seeking a new and effective treatment to help combat high rates of morbidity and mortality in patients suffering from life-threatening invasive fungal infections," said Dr. Angulo. "With the potential for both oral and intravenous formulations, SCY-078 could be a suitable alternative for treating these infections. Moreover, with its activity against multi-drug resistant pathogens, SCY-078 may represent a solution to the growing problem of resistance to currently available antifungals. I look forward to joining the SCYNEXIS team to advance SCY-078."
SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com.
CONTACT: Media Relations Heather Savelle MacDougall Biomedical Communications Tel: 781.235.3060 firstname.lastname@example.org Investor Relations Jillian Connell The Trout Group LLC Tel: 646.378.2956 email@example.com SCYNEXIS, Inc. Chuck Osborne Chief Financial Officer Tel: 919.544.5600 firstname.lastname@example.orgSource: SCYNEXIS, Inc.
Released May 14, 2015